An open, prospective cohort study of VV116 in Chinese participants infected with SARS-CoV-2 omicron variants
Yinzhong Shen, Jingwen Ai, Na Lin, Haocheng Zhang, Yang Li, Hongyu Wang, Sen Wang, Zhen Wang, Tao Li, Feng Sun, Zhenyu Fan, Liqun Li, Yunfei Lu, Xianmin Meng, Hong Xiao, Huiliang Hu, Yun Ling, Feng Li, Hongdi Li, Chunmei Xi, Liping Gu, Wenhong Zhang, Xiaohong Fan
Emerging Microbes & Infections, doi:10.1080/22221751.2022.2078230
Omicron variant of SARS-CoV-2 has become the predominant variant worldwide. VV116 is an oral drug with robust anti-SARS-CoV-2 efficacy in preclinical studies. We conducted an open, prospective cohort study to evaluate its safety and effectiveness in Chinese participants infected with the omicron variant from March 8th, 2022 to March 24th, 2022. 136 hospitalized nonsevere patients confirmed with COVID-19 were enrolled including 60 patients who received VV116 (300 mg, BID×5 days) in the treatment group and 76 patients who didn't receive VV116 in the control group besides standard treatment. Viral load shedding time and adverse events were collected during the follow-up. There was no significant difference in baseline characteristics between the VV116 group and the control group, except for a higher symptom prevalence in the control group (P = 0.021). The median time from the first positive test to the first VV116 administration was 5 (range: 2-10) days. Participants who received VV116 within 5 days since the first positive test had a shorter viral shedding time than the control group (8.56 vs 11.13 days), and cox regression analysis showed adjusted HR of 2.37 [95%CI 1.50-3.75], P < 0.001. In symptomatic subgroup, VV116 group had a shorter viral shedding time than the control group (P = 0.016). A total of 9 adverse events with no serious adverse events were reported in the VV116 group, all of them were resolved without intervention. VV116 is a safe, effective oral antiviral drug, which shows a better performance within the early onset of omicron infection.
References
Bernal, Da Silva, Musungaie, Molnupiravir for oral treatment of COVID-19 in nonhospitalized patients, N Engl J Med
Christensen, Olsen, Long, Signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with Coronavirus disease 2019 caused by the omicron variant of severe acute Respiratory syndrome Coronavirus 2 in Houston, Texas, Am J Pathol
Dejnirattisai, Huo, Zhou, SARS-CoV-2 Omicron-B.1.1.529 leads to widespread escape from neutralizing antibody responses, Cell
Ekpanyapong, Bunchorntavakul, Reddy, COVID-19 and the liver: lessons learnt from the EAST and the WEST, A year later, J Viral Hepat
Hammond, Leister-Tebbe, Gardner, Oral nirmatrelvir for high-risk, Nonhospitalized adults with COVID-19, N Engl J Med
Mahase, COVID-19: Pfizer's paxlovid is 89% effective in patients at risk of serious illness, company reports, Br Med J
Qian, Wang, Zhang, Safety, tolerability, and pharmacokinetics of VV116, an oral nucleoside analog against SARS-CoV-2, in Chinese healthy subjects, Acta Pharmacol Sin,
doi:10.1038/s41401-022-00895-6Spinner, Gottlieb, Criner, Effect of Remdesivir vs standard care on Clinical status at 11 days in patients With moderate COVID-19: A randomized clinical trial, JAMA
Takashita, Kinoshita, Yamayoshi, Efficacy of antiviral agents against the SARS-CoV-2 Omicron Subvariant BA.2, N Engl J Med
Vangeel, Chiu, Jonghe, Molnupiravir and Nirmatrelvir remain active against SARS-CoV-2 Omicron and other variants of concern, Antiviral Res
Wang, Zhang, Du, Remdesivir in adults with severe COVID-19: a randomised, double-blind, placebo-controlled, multicentre trial, The Lancet
Xie, Yin, Zhang, Design and development of an oral remdesivir derivative VV116 against SARS-CoV-2, Cell Res
Zhang, Shi, Wang, Liver injury in COVID-19: management and challenges, Lancet Gastroenterol Hepatol
Zhou, Yu, Du, Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study, The Lancet
